Jon Moore joined Horizon Discovery to manage its portfolio of target validation alliances in 2012 and became CSO in 2014. He leads a broad ranging internal research program that aims to deliver opportunities for spin out companies and also milestoned licensing deals. These have been focussed on synthetic lethal and immuno-oncology approaches to cancer, but are now shifting to encompass cell therapies. He is a Director of Avvinity Therapeutics, a joint venture between Horizon and Centauri Therapeutics that is exploring the potential of a novel ablative therapy for cancer. Prior to joining Horizon, Jon spent 10 years in drug discovery at Vernalis and prior to that he had extensive research experience in the laboratories of Sally Kornbluth and Nobel Prize winner, Tim Hunt.